Butyphthalide in Combination With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT03394950

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Hui-Sheng Chen (from the registry)
Registry
  • NCT NCT03394950
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03394950. Randomized; double masking; primary purpose prevention. Start 2018-05-25 (actual); primary completion 2021-05-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Butyphthalide in Combination With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke
Condition
Stroke, Ischemic
Intervention (Drug)
Butyphthalide combined with rtPA
Intervention (Drug)
rtPA
Lead sponsor
Hui-Sheng Chen (class: other)

Record details

Record id
cardio:ct-nct03394950
Content hash
bcdf0c6f74af857a7686fd5320974569d525f4f3bb59ca450f4faa1fbb4bc661